InflaRx N.V. (IFRX) News
NASDAQ: IFRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.04-0.05 (-4.59%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IFRX news summary
We found 7 recent headlines mentioning InflaRx N.V. (IFRX): 0 in the past week and 5 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, IFRX is down 4.59% at $1.04. The most recent story, "InflaRx Publishes First-In-Human Phase 1 Results For Izicopan; Stock Up", was published by Nasdaq on Nov 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest InflaRx N.V. headlines
- InflaRx Publishes First-In-Human Phase 1 Results For Izicopan; Stock Up(RTTNews) - InflaRx N.V. (IFRX), a biopharmaceutical company developing anti-inflammatory therapeutics, announced the peer-reviewed publication of first-in-human Phase 1 clinical data for izicopan,…NasdaqIFRX, LEN.B
- InflaRx N.V. Announces Publication of Phase 1 Data for IzicopanInflaRx N.V. announced the peer-reviewed publication of first-in-human Phase 1 clinical data for izicopan, formerly known as INF904, the Company’s orally administered, next-generation small…Nasdaq
- InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of IzicopanJena, Germany, Nov. 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…GlobeNewswire
- InflaRx N.V. Reports €18.7 million Net Loss for the Nine Months Ended September 30, 2026InflaRx N.V. reported its financial results for the nine months ended September 30, 2026, incurring a net loss of €18.7 million. The company realized no revenues for the nine months ended…Nasdaq
- InflaRx Announces November Investor EventsJena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…GlobeNewswire
- InflaRx N.V. Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026InflaRx N.V. announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology’s Kidney Week 2026. The in vivo and in vitro data…Nasdaq
- InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…GlobeNewswire